Who is the sponsor?
Comentis, Inc.
Who are the patients?
Patients who receive frequent anti-vegf injections for recurrent macular edema due to neovascular AMD and have shown past resolution of leakage following anti-vegf treatment.
How long is the trial?
Participants are monitored monthly for one year.
What is this study investigating?
To determine if the combination of ATG003 (an eye drop) administered twice daily by the patient with LucentisTM or AvastinTM can reduce the number of injections required and reduce the need for repeat injections.
How is the treatment administered?
The experimental compound is a clear liquid that is administered topically to the eye via an eye drop.